tetano
Editor, Senior Moderator
Trop Med Infect Dis
. 2022 Apr 16;7(4):62.
doi: 10.3390/tropicalmed7040062.
Cubital Tunnel Syndrome Temporally after COVID-19 Vaccination
Luca Roncati[SUP] 1 [/SUP], Davide Gravina[SUP] 2 [/SUP], Caterina Marra[SUP] 3 [/SUP], Norman Della Rosa[SUP] 4 [/SUP], Roberto Adani[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is the most dramatic pandemic of the new millennium. To counter it, specific vaccines have been launched in record time under emergency use authorization or conditional marketing authorization and have been subjected to additional monitoring. The European Medicines Agency recommend reporting any suspected adverse reactions during this additional monitoring phase. For the first time in the available medical literature, we report a left cubital tunnel syndrome in a 28-year-old right-handed healthy male after seven days from the first dose of Spikevax[SUP]®[/SUP] (formerly Moderna COVID-19 Vaccine). Histochemistry for Alcian Blue performed on the tissue harvested from the cubital site reveals myxoid degeneration of the small nerve collaterals, a clear sign of nerve injury. It still remains unclear why the syndrome occurs in a localized and not generalized form to all osteofibrous tunnels. Today, modified messenger ribonucleic acid vaccines as Spikevax[SUP]®[/SUP] represent an avantgarde technological platform with a lot of potential, but one which needs careful monitoring in order to identify in advance those patients who may experience adverse events after their administration.
Keywords: Alcian Blue stain; Spikevax®; coronavirus disease 2019 (COVID-19); cubital tunnel syndrome; histochemistry; modRNA COVID-19 vaccine; modified messenger ribonucleic acid (modRNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); ulnar neuropathy; vaccines.
. 2022 Apr 16;7(4):62.
doi: 10.3390/tropicalmed7040062.
Cubital Tunnel Syndrome Temporally after COVID-19 Vaccination
Luca Roncati[SUP] 1 [/SUP], Davide Gravina[SUP] 2 [/SUP], Caterina Marra[SUP] 3 [/SUP], Norman Della Rosa[SUP] 4 [/SUP], Roberto Adani[SUP] 4 [/SUP]
Affiliations
- PMID: 35448837
- DOI: 10.3390/tropicalmed7040062
Abstract
Coronavirus disease 2019 (COVID-19) is the most dramatic pandemic of the new millennium. To counter it, specific vaccines have been launched in record time under emergency use authorization or conditional marketing authorization and have been subjected to additional monitoring. The European Medicines Agency recommend reporting any suspected adverse reactions during this additional monitoring phase. For the first time in the available medical literature, we report a left cubital tunnel syndrome in a 28-year-old right-handed healthy male after seven days from the first dose of Spikevax[SUP]®[/SUP] (formerly Moderna COVID-19 Vaccine). Histochemistry for Alcian Blue performed on the tissue harvested from the cubital site reveals myxoid degeneration of the small nerve collaterals, a clear sign of nerve injury. It still remains unclear why the syndrome occurs in a localized and not generalized form to all osteofibrous tunnels. Today, modified messenger ribonucleic acid vaccines as Spikevax[SUP]®[/SUP] represent an avantgarde technological platform with a lot of potential, but one which needs careful monitoring in order to identify in advance those patients who may experience adverse events after their administration.
Keywords: Alcian Blue stain; Spikevax®; coronavirus disease 2019 (COVID-19); cubital tunnel syndrome; histochemistry; modRNA COVID-19 vaccine; modified messenger ribonucleic acid (modRNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); ulnar neuropathy; vaccines.